Lithium Australia prepares to drill Horseshoe Pegmatite Prospect

|

Published 10-JUL-2017 12:29 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Shares in Lithium Australia (ASX:LIT) surged more than 40% under record trading volumes on Friday after the company informed the market that it was ready to commence drilling at the Horseshoe Pegmatite Prospect. This is part of LIT’s Ravensthorpe lithium project which is situated 500 kilometres south-east of Perth.

It should be noted that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

In terms of its location, it is arguably of more significance that it is only 18 kilometres from Galaxy Resources’ (ASX: GXY) Mt Cattlin lithium mine. It is possible that positive news also released by GXY last week provided additional momentum for LIT’s share price.

With an 800 metre by 800 metre flat lying footprint containing both lepidolite and spodumene, the Horseshoe Pegmatite shows strong geological similarities to mineralisation at Mt Cattlin.

Ravensthorpe lithium project LIT

After a weak share price performance in the first half of calendar year 2017, GXY started the year on a strong note with its share price increasing from $1.65 as at June 30 to close the week at $2.10 last Friday, representing an increase of 27%.

Again share trading performance should not be used as the basis for an investment as it does fluctuate and investors should approach any investment decision with caution.

GXY’s price increase made it the best performing ASX 200 stock for the first week of fiscal 2018, and interestingly there was a strong performance from another specialty metals play in emerging graphite producer, Syrah Resources (ASX: SYR) which delivered a week on week gain of 18%.

While GXY’s strong kick was possibly assisted by the absence of tax loss selling that occurred in June, there was also strong news on the operational front as recoveries of 61% from production of circa 14,000 dmt were achieved, well in excess of initial targets of between 50% and 55%.

This augurs well for a company such as LIT should the mineralisation at its Horseshoe Pegmatite be also deemed to offer robust percentage recoveries when converted to lithium concentrate.

The lithium mineralisation at LIT’s prospect is hosted by the Cocanarup swarm, and a recently excavated costean has revealed lithium mineralisation which includes spodumene, lepidolite and elbaite, all of which can be processed using the company’s proprietary Sileach process.

tags

LITHIUM


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X